878 related articles for article (PubMed ID: 26419263)
21. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins.
Dev A; Byrne SM; Verma R; Ashton-Rickardt PG; Wojchowski DM
J Exp Med; 2013 Feb; 210(2):225-32. PubMed ID: 23319700
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin receptor response circuits.
Wojchowski DM; Sathyanarayana P; Dev A
Curr Opin Hematol; 2010 May; 17(3):169-76. PubMed ID: 20173635
[TBL] [Abstract][Full Text] [Related]
24. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy.
Lappin KM; Mills KI; Lappin TR
Stem Cells Transl Med; 2021 Jun; 10(6):836-843. PubMed ID: 33475252
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
27. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin Signaling in the Microenvironment of Tumors and Healthy Tissues.
Liu W; Varier KM; Sample KM; Zacksenhaus E; Gajendran B; Ben-David Y
Adv Exp Med Biol; 2020; 1223():17-30. PubMed ID: 32030683
[TBL] [Abstract][Full Text] [Related]
29. Iron Metabolism in Chronic Kidney Disease Patients.
Honda H; Hosaka N; Ganz T; Shibata T
Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin regulation of red blood cell production: from bench to bedside and back.
Bhoopalan SV; Huang LJ; Weiss MJ
F1000Res; 2020; 9():. PubMed ID: 32983414
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin use in CKD patients with cancer: to tread with caution?
Nayak-Rao S; McCormick B
J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
[TBL] [Abstract][Full Text] [Related]
32. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection.
Chang ZY; Chiang CH; Lu DW; Yeh MK
Expert Opin Drug Deliv; 2008 Dec; 5(12):1313-21. PubMed ID: 19040394
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietin: physiology and pharmacology update.
Fisher JW
Exp Biol Med (Maywood); 2003 Jan; 228(1):1-14. PubMed ID: 12524467
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
35. In vivo regulation of erythropoiesis by chemically inducible dimerization of the erythropoietin receptor intracellular domain.
Suzuki N; Mukai HY; Yamamoto M
PLoS One; 2015; 10(3):e0119442. PubMed ID: 25790231
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.
Debeljak N; Sytkowski AJ
Curr Pharm Des; 2008; 14(13):1302-10. PubMed ID: 18537654
[TBL] [Abstract][Full Text] [Related]
37. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
38. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury.
Salahudeen AK; Haider N; Jenkins J; Joshi M; Patel H; Huang H; Yang M; Zhe H
Am J Physiol Renal Physiol; 2008 Jun; 294(6):F1354-65. PubMed ID: 18385271
[TBL] [Abstract][Full Text] [Related]
39. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
[TBL] [Abstract][Full Text] [Related]
40. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.
Hara A; Koshino Y; Kurokawa Y; Shinozaki Y; Miyake T; Kitajima S; Toyama T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Nakamura H; Wada T
Clin Exp Nephrol; 2020 Jan; 24(1):88-95. PubMed ID: 31502102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
